-
Bajaj Healthcare gains over 5% after getting DRDO license to manufacture, sale of 2-DG drug
The DRDO has granted permission to manufacture and market the 2-Deoxy-D-Glucose” in the domestic market
-
Bajaj Healthcare hits record highs on applying patent for Covid drug
After scaling fresh peak, the scrip closed with a 13% gain at Rs 813.35 apiece on the BSE
-
Bajaj Healthcare launches drug to treat black fungus infection in Covid-19 patients
Posaconazole is a triazole antifungal agent indicated for treating Mucormycosis patients
